SPRO (Spero Therapeutics) Moat Score: 5/10 (As of Jun. 26, 2026)


SPRO Spero Therapeutics Inc SPRO
55 GF Score
Price $2.02
GF Value $1.06
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Spero Therapeutics Moat Score?

Spero Therapeutics SPRO -4.04% 55 Moat Score is 5 as of Jun. 26, 2026. GuruFocus rates SPRO with a GF Score™ of 55/100 and a GF Value™ of $1.06 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 1,404 Biotechnology companies, Spero Therapeutics ranks better than 96.72% on this metric.

Spero Therapeutics has the Moat Score of 5, which implies that the company might have Narrow Moat - Solid narrow moat.

Spero Therapeutics has Narrow Moat: Spero Therapeutics has a solid narrow moat due to its focus on developing novel antibiotics and some valuable patents. However, it lacks strong brand strength, significant customer switching costs, and durable cost advantages, limiting its competitive edge.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Spero Therapeutics might have Narrow Moat - Solid narrow moat.

Spero Therapeutics  (NAS:SPRO) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Spero Therapeutics Moat Score Related Terms

SPRO vs ORMP, PLYX, HRTX: Moat Score Comparison

For the Biotechnology subindustry, Spero Therapeutics's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Spero Therapeutics Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Spero Therapeutics's Moat Score distribution charts can be found below:

* The bar in red indicates where Spero Therapeutics's Moat Score falls into.


SPRO
55GF Score
Spero Therapeutics Inc SPRO
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 5 mean?
Spero Therapeutics (SPRO) has a Moat Score of 5 as of Jun. 26, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Spero Therapeutics ranks #46 out of 1404 companies in the Biotechnology industry, placing it in the top 3.3%.
Is Spero Therapeutics' Moat Score too high?
Spero Therapeutics' current Moat Score is 5. The Biotechnology industry median Moat Score is 2.00. Spero Therapeutics' value of 5 is 150% above this industry median. Based on the distribution chart, Spero Therapeutics ranks #46 out of 1404 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Spero Therapeutics has a GF Score™ of 55/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Spero Therapeutics' Moat Score compare to ORMP and PLYX?
According to the Biotechnology industry distribution chart, Spero Therapeutics ranks #46 out of 1404 companies for Moat Score. This places Spero Therapeutics in the top 3% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. Spero Therapeutics' value of 5 is 150% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,404 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Spero Therapeutics's current Moat Score of 5 is 150% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Spero Therapeutics's current Moat Score is 5. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Spero Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Spero Therapeutics (SPRO) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.06, compared to a current price of $2.02 — trading 90.6% above its estimated fair value. The current Moat Score is 5 and 150% above the Biotechnology industry median of 2.00. Spero Therapeutics' overall GF Score™ is 55/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Spero Therapeutics (SPRO), the current Moat Score is 5 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Spero Therapeutics (SPRO) Overvalued in 2026?

Based on GuruFocus' analysis, Spero Therapeutics stock appears to be overvalued. The current stock price of $2.02 is trading 90.6% above its estimated GF Value™ of $1.06. GuruFocus considers Spero Therapeutics to be Significantly Overvalued.

Key valuation signals for SPRO:

  • Moat Score: 5
  • GF Value™: $1.06 vs. price of $2.02 (90.6% above fair value)
  • GF Score™: 55/100 with 4 warning signs
  • Industry Position: 150% above the Biotechnology median (#46 of 1404)

No single metric tells the full story. See the SPRO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Spero Therapeutics Business Description

Other Exchanges 2HA:Germany
Address 675 Massachusetts Avenue, 14th Floor, Cambridge, MA, USA, 02139
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
55GF Score

Get the complete analysis for SPRO

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.02
Price
$1.06
GF Value